2023考研英語閱讀無疆界之戰
TO GET an idea of where the worldspharmaceutical industry is heading, a leafycomplex tucked off a hectic road in Mumbaiprovides a clue. In one part of the building, Abbott,an American firm, is developing generic drugsaprivilege it won when it bought the copycatbusiness of Piramal, an Indian firm, for $3.7 billionin 2010. In the other part of the building Piramal isdeveloping new drugs. The American firm wants tosell cheap generics in India; the Indian firm plans tosell original drugs in America. One might think thatthey were having an identity crisis, if each were not so excited by the switch.
要想知道世界制藥行業發展趨勢如何，只要看看位于孟買一條繁忙的街道旁的一座葉狀的綜合大樓便可略知一二。這座大樓的一側駐扎著美國雅培公司，目前正忙于仿制藥品的開發。該公司于2010年以37億美元收購了印度制藥公司皮拉馬爾旗下的品牌仿制藥業務，因而擁有了生產仿制藥的特權。大樓的另一側是致力于開發新藥的皮拉馬爾公司。美國公司欲在印度銷售廉價的仿制藥，而印度公司則計劃將新藥出售給美國市場。如果不是各自都對這種轉換如此興奮，人們或許認為這兩家公司可能正面臨著身份危機。
The worlds drug industry is in flux. In the past, Western drugmakers thrived on innovationwhile firms in emerging markets made cheap copies of their products. Now they areinvading each others turf. Blockbuster drugs are losing their patents and, despite some brightspots, research has become more costly and less fruitful. Big Western firms are nowlooking to emerging markets for growth, hoping to sell not just their patented drugs butgeneric ones, too. Firms in emerging markets are expanding their footprint, ramping upsales in the West and investing in research. It is an energetic exchange, but a risky one.
全球制藥行業處于不斷變化之中。過去，西方制藥企業靠創新而繁榮，而新興市場的制藥公司則靠廉價的仿制藥賺錢。而今，他們正在互相侵入彼此的地盤。暢銷藥面臨失去專利保護之憂，盡管研發會帶來一定的競爭力，但研發的成本越來越高，成果卻越來越少。西方大型制藥公司目前正轉向新興市場尋求增長，他們希望不僅僅出售專利藥品，還包括仿制藥。新興市場的制藥公司也在擴大他們的足跡，不斷提高在西方市場的銷售額并加大研發的投入。這是一種極具活力的轉換，同時也很冒險。
It is no surprise that Western drugmakers are looking further afield. Americas spending onprescription drugs increased by just 2.3% in 2010. As incomes rise elsewhere, the demandfor health care grows. IMS Health, a research group, expects emerging markets share ofdrug spending to jump from 12% in 2005 to 28% in 2023.
西方藥廠不斷向外擴張地盤，這一點毫不奇怪。2010年，美國的處方藥支出僅上升了2.3%。而隨著世界其它地區的收入提高，人們對醫療保健的需求也隨之上升。據全球研究機構IMS Health預測，新興市場的藥品支出所占比例將由2005年的12%躍升至2023年的28%。
Western companies are keen to tap this growth. Sanofi-Aventis, a French giant, has becomethe biggest producer of generic drugs in Latin America after its purchase in 2010 of Medley,a Brazilian firm. Not to be left out, Americas Pfizer, the worlds biggest drugmaker, bought40% of Teuto, a Brazilian generics company. Some firms also hope that developing countriesmany chock full of talented scientistswill help to fill their bare pipelines with new drugs.Merck, for example, recently announced that it would create a new research anddevelopment centre in Beijing, investing $1.5 billion over five years.
西方藥企熱衷于培育這一增長。法國醫藥巨頭賽諾菲安萬特公司在2010年收購巴西公司Medley之后一躍成為拉美地區最大的仿制藥生產企業。同時，世界最大的藥品制造商---美國的輝瑞公司也不甘示弱地買下了Teuto40%的股份。一些公司還希望，發展中國家眾多才華橫溢的科學家可幫助他們在日已枯竭的研發產品線中注入新藥。例如，默克最近宣布，它將在5年內投資15億美元在北京建立一個研發中心
TO GET an idea of where the worldspharmaceutical industry is heading, a leafycomplex tucked off a hectic road in Mumbaiprovides a clue. In one part of the building, Abbott,an American firm, is developing generic drugsaprivilege it won when it bought the copycatbusiness of Piramal, an Indian firm, for $3.7 billionin 2010. In the other part of the building Piramal isdeveloping new drugs. The American firm wants tosell cheap generics in India; the Indian firm plans tosell original drugs in America. One might think thatthey were having an identity crisis, if each were not so excited by the switch.
要想知道世界制藥行業發展趨勢如何，只要看看位于孟買一條繁忙的街道旁的一座葉狀的綜合大樓便可略知一二。這座大樓的一側駐扎著美國雅培公司，目前正忙于仿制藥品的開發。該公司于2010年以37億美元收購了印度制藥公司皮拉馬爾旗下的品牌仿制藥業務，因而擁有了生產仿制藥的特權。大樓的另一側是致力于開發新藥的皮拉馬爾公司。美國公司欲在印度銷售廉價的仿制藥，而印度公司則計劃將新藥出售給美國市場。如果不是各自都對這種轉換如此興奮，人們或許認為這兩家公司可能正面臨著身份危機。
The worlds drug industry is in flux. In the past, Western drugmakers thrived on innovationwhile firms in emerging markets made cheap copies of their products. Now they areinvading each others turf. Blockbuster drugs are losing their patents and, despite some brightspots, research has become more costly and less fruitful. Big Western firms are nowlooking to emerging markets for growth, hoping to sell not just their patented drugs butgeneric ones, too. Firms in emerging markets are expanding their footprint, ramping upsales in the West and investing in research. It is an energetic exchange, but a risky one.
全球制藥行業處于不斷變化之中。過去，西方制藥企業靠創新而繁榮，而新興市場的制藥公司則靠廉價的仿制藥賺錢。而今，他們正在互相侵入彼此的地盤。暢銷藥面臨失去專利保護之憂，盡管研發會帶來一定的競爭力，但研發的成本越來越高，成果卻越來越少。西方大型制藥公司目前正轉向新興市場尋求增長，他們希望不僅僅出售專利藥品，還包括仿制藥。新興市場的制藥公司也在擴大他們的足跡，不斷提高在西方市場的銷售額并加大研發的投入。這是一種極具活力的轉換，同時也很冒險。
It is no surprise that Western drugmakers are looking further afield. Americas spending onprescription drugs increased by just 2.3% in 2010. As incomes rise elsewhere, the demandfor health care grows. IMS Health, a research group, expects emerging markets share ofdrug spending to jump from 12% in 2005 to 28% in 2023.
西方藥廠不斷向外擴張地盤，這一點毫不奇怪。2010年，美國的處方藥支出僅上升了2.3%。而隨著世界其它地區的收入提高，人們對醫療保健的需求也隨之上升。據全球研究機構IMS Health預測，新興市場的藥品支出所占比例將由2005年的12%躍升至2023年的28%。
Western companies are keen to tap this growth. Sanofi-Aventis, a French giant, has becomethe biggest producer of generic drugs in Latin America after its purchase in 2010 of Medley,a Brazilian firm. Not to be left out, Americas Pfizer, the worlds biggest drugmaker, bought40% of Teuto, a Brazilian generics company. Some firms also hope that developing countriesmany chock full of talented scientistswill help to fill their bare pipelines with new drugs.Merck, for example, recently announced that it would create a new research anddevelopment centre in Beijing, investing $1.5 billion over five years.
西方藥企熱衷于培育這一增長。法國醫藥巨頭賽諾菲安萬特公司在2010年收購巴西公司Medley之后一躍成為拉美地區最大的仿制藥生產企業。同時，世界最大的藥品制造商---美國的輝瑞公司也不甘示弱地買下了Teuto40%的股份。一些公司還希望，發展中國家眾多才華橫溢的科學家可幫助他們在日已枯竭的研發產品線中注入新藥。例如，默克最近宣布，它將在5年內投資15億美元在北京建立一個研發中心
